

01-03-06

fw

EXPRESS MAIL NO.: EV452776144US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: George W. Muller *et al.*

Group Art Unit: 1614

Serial No.: 10/715,184

Examiner: To be assigned

Filed: November 17, 2003

Attorney Docket No.: 501872-999056  
(9516-057-999)

For: METHODS OF USING AND COMPOSITIONS  
COMPRISING (-)-3-(3,4-DIMETHOXY-  
PHENYL)-3-(1-OXO-1,3-DIHYDRO-  
ISOINDOL-2-YL)-PROPIONAMIDE

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **A83-A94** and **C04-C10** listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." This Information Disclosure Statement supplements the Information Disclosure Statement filed on September 22, 2004.


Copies of references **A83** and **C04-C10** are provided herewith. Copies of references **A84-A94**, which are either United States patents or patent publications, are not submitted herewith pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. **503013**.

Respectfully submitted,

Date: December 30, 2005

  
\_\_\_\_\_  
Yeahsil Moon (Reg. No.)  
For: Anthony M. Insogna 52,042  
35,203  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)ATTY. DOCKET NO.  
501872-999056  
(9516-057-999)APPLICATION NO.  
10/715,184APPLICANT  
Muller et al.FILING DATE  
Nov. 17, 2003GROUP  
1614**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A83	60/427,379		Muller et al. (9516-058-888)			11/18/2002
	A84	2005/0014727	01-20-05	Muller et al.			
	A85	2004/0167199	08-26-04	Muller et al.			
	A86	2004/0167174	08-26-04	Man et al.			
	A87	2004/0147588	07-29-04	Man et al.			
	A88	2004/006096	01-08-04	Muller et al.			
	A89	2004/0019106	01-29-04	Muller et al.			
	A90	2003/0187052	10-02-03	Muller et al.			
	A91	2003/0045726	03-06-03	Muller et al.			
	A92	6,844,359	01-18-05	Muller			
	A93	6,897,231	05-24-05	Bhagwat et al.			
	A94	6,911,464	06-28-05	Man et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B01						
	B02						
	B03						

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C04	Beavo et al., 1990, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors," Trends Pharmacol. Sci. 11(4):150-155
	C05	Carstensen, 1995, Drug Stability: Principles & Practice, 2 <sup>nd</sup> ed., Marcel Dekker, New York, NY pp. 379-380
	C06	Hidaka et al., 1976, "Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase," Biochim. Biophys. Acta. 429(2):485-497
	C07	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity," J. Med. Chem. 39(17):3238-3240
	C08	Nicholson et al., 1991, "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes," Trends. Pharmacol. Sci. 12(1):19-27
	C09	Wilens, 1972, Tables of Resolving Agents and Optical Resolutions, Eliel, ed., Univ. Notre Dame Press, Notre Dame, IN, pp. 268
	C10	Wolff, ed., 1995, Burger's Medicinal Chemistry and Drug Discovery, 5 <sup>th</sup> ed., 172-178, 949-982

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.